VIDEOS
Chemical SOP
Microbiology SOP
Warehouse SOP
Manufacturing SOP
Information technology SOP

PARACETAMOL, BROMHEXINE HYDROCHLORIDE, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE & GUAIPHENESIN TABLETS

Explore the Batch Manufacturing Record (BMR), manufacturing process, Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) of combination tablets.

1. Introduction to Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Guaiphenesin Tablets (BMR):

The Batch Manufacturing Record (BMR) of Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Guaiphenesin Tablets is an essential pharmaceutical document that provides comprehensive instructions for manufacturing, processing, quality control, and documentation of this combination formulation in accordance with Good Manufacturing Practices (GMP). This multi-ingredient tablet formulation combines five active pharmaceutical ingredients intended to provide symptomatic relief from cold, cough, fever, nasal congestion, and associated respiratory symptoms. Paracetamol acts as an analgesic and antipyretic, Bromhexine Hydrochloride functions as a mucolytic agent, Chlorpheniramine Maleate provides antihistaminic activity, Phenylephrine Hydrochloride acts as a nasal decongestant, and Guaiphenesin serves as an expectorant. The BMR includes detailed procedures for raw material dispensing, sifting, granulation, drying, blending, lubrication, compression, and packaging. It also specifies equipment requirements, environmental conditions, in-process quality checks, material reconciliation, and batch documentation. Critical quality parameters such as tablet weight variation, hardness, thickness, friability, disintegration, and assay are monitored to ensure consistent product quality. Proper execution of the BMR ensures manufacturing traceability, process consistency, regulatory compliance, and effective quality assurance throughout production. It also supports deviation investigation, batch review, and final product release by authorized Quality Assurance personnel.

Skip to PDF content

2. Manufacturing Process Flow Diagram of Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Guaiphenesin Tablets (BMR):

The manufacturing process flow diagram illustrates the sequential operations involved in producing Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride, and Guaiphenesin Tablets under Good Manufacturing Practices (GMP). The manufacturing process begins with raw material dispensing, where active pharmaceutical ingredients (APIs) and excipients are weighed according to the approved Batch Manufacturing Record (BMR). Dispensed materials undergo sifting to remove foreign particles and obtain suitable particle sizes. During wet granulation, the materials are mixed using starch paste to form granules. These granules are dried in a Fluid Bed Dryer (FBD), followed by sizing through a multimill to achieve the required granule distribution.

The dried granules undergo blending and lubrication to ensure uniform distribution and suitable compression characteristics. Subsequently, the lubricated blend is compressed into tablets using a rotary compression machine. Critical in-process quality checks include tablet weight variation, hardness, thickness, friability, appearance, and disintegration. After compression, tablets undergo dedusting and blister packaging. Packaging integrity, labeling accuracy, and product identification are verified. Finally, finished tablets undergo Quality Control testing, batch documentation review, and Quality Assurance approval before release for distribution, ensuring product quality, consistency, traceability, and regulatory compliance.

3. Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Guaiphenesin Tablets:

Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) are essential elements in ensuring the consistent manufacturing quality, safety, and efficacy of Paracetamol, Bromhexine Hydrochloride, Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Guaiphenesin Tablets under Good Manufacturing Practices (GMP).

Critical Process Parameters (CPPs) are manufacturing variables that require monitoring and control to maintain product quality. During sifting, sieve mesh size is controlled to achieve suitable particle distribution. Wet granulation parameters include impeller speed, chopper speed, binder concentration, granulation time, and endpoint determination. Drying parameters include inlet temperature, outlet temperature, drying duration, and loss on drying (LOD). Blending and lubrication require control of mixing time, blender speed, and lubricant quantity. Compression parameters include compression force, turret speed, and tablet weight adjustment. Packaging parameters include sealing temperature, pressure, and machine speed.

Critical Quality Attributes (CQAs) include tablet appearance, identification, weight variation, thickness, hardness, friability, disintegration time, assay, content uniformity where applicable, and dissolution performance. Effective monitoring of CPPs and verification of CQAs help minimize manufacturing deviations, maintain batch-to-batch consistency, and ensure compliance with approved specifications. process controls, validated manufacturing procedures, and Quality Assurance oversight support reliable production and consistent finished product quality.

Community
error: Content is protected !!

This is the Premium Content

You can access this page after paying the subscription fees of 21 ₹ /month only.